Free Trial

Pfizer (PFE) Stock Forecast & Price Target

Pfizer logo
$22.50 +0.66 (+3.02%)
Closing price 03:59 PM Eastern
Extended Trading
$22.51 +0.01 (+0.04%)
As of 06:42 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Pfizer - Analysts' Recommendations and Stock Price Forecast (2025)

MarketBeat calculates consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0 to .5 = Strong Sell, .5 to 1 = Sell, 1 to 1.5 = Reduce, 1.5 to 2.5 = Hold, 2.5 to 3.0 = Moderate Buy, 3.0 to 3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.

Consensus Rating

Sell
1
Hold
8
Buy
8

Based on 17 Wall Street analysts who have issued ratings for Pfizer in the last 12 months, the stock has a consensus rating of "Moderate Buy." Out of the 17 analysts, 1 has given a sell rating, 8 have given a hold rating, 5 have given a buy rating, and 3 have given a strong buy rating for PFE.

Consensus Price Target

$31.07
38.10% Upside
According to the 17 analysts' twelve-month price targets for Pfizer, the average price target is $31.07. The highest price target for PFE is $45.00, while the lowest price target for PFE is $24.00. The average price target represents a forecasted upside of 38.10% from the current price of $22.50.
Get the Latest News and Ratings for PFE and Related Stocks

Enter your email address to receive the latest news and analysts' ratings for Pfizer and its competitors.

Sign Up

PFE Analyst Ratings Over Time

TypeCurrent Forecast
4/9/24 to 4/9/25
1 Month Ago
3/10/24 to 3/10/25
3 Months Ago
1/10/24 to 1/9/25
1 Year Ago
4/10/23 to 4/9/24
Strong Buy
3 Strong Buy rating(s)
3 Strong Buy rating(s)
2 Strong Buy rating(s)
0 Strong Buy rating(s)
Buy
5 Buy rating(s)
5 Buy rating(s)
5 Buy rating(s)
6 Buy rating(s)
Hold
8 Hold rating(s)
8 Hold rating(s)
8 Hold rating(s)
11 Hold rating(s)
Sell
1 Sell rating(s)
1 Sell rating(s)
1 Sell rating(s)
0 Sell rating(s)
Consensus Price Target$31.07$31.92$32.00$36.88
Forecasted Upside38.10% Upside19.90% Upside18.87% Upside37.72% Upside
Consensus Rating
Moderate Buy
Moderate Buy
Moderate Buy
Hold
Remove Ads

PFE Analyst Recommendations By Month

The chart below shows how a company's ratings by analysts have changed over time. Each bar represents the previous year of ratings for that month. Within each bar, the sell ratings are shown in red, the hold ratings are shown in yellow, the buy ratings are shown in green, and the strong buy ratings are shown in dark green.
Skip Chart & View Analyst Rating History

PFE Price Targets by Month

The chart below shows how a company's share price and consensus price target have changed over time. The dark blue line represents the company's actual price. The lighter blue line represents the stock's consensus price target. The even lighter blue range in the background of the two lines represents the low price target and the high price target for each stock.
Skip Chart and View Analyst Price Target HistorySkip Chart & View Price History Table

Pfizer Stock vs. The Competition

TypePfizerMedical CompaniesS&P 500
Consensus Rating Score
2.59
2.82
2.54
Consensus RatingModerate BuyModerate BuyModerate Buy
Predicted Upside38.10% Upside16,111.79% Upside24.77% Upside
News Sentiment Rating
Positive News

See Recent PFE News
Positive News
Positive News
Remove Ads
DateBrokerageAnalyst NameActionRatingPrice TargetUpside/Downside on Report DateDetails
4/8/2025UBS Group
3 of 5 stars
Trung Huynh
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower TargetNeutral ➝ Neutral$28.00 ➝ $24.00+10.37%
4/8/2025The Goldman Sachs Group
3 of 5 stars
Asad Haider
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Neutral$32.00 ➝ $25.00+13.00%
3/27/2025Citigroup
2 of 5 stars
 Reiterated RatingNeutral ➝ Neutral
3/18/2025Guggenheim
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Vamil Divan
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy
3/10/2025Hsbc Global Res
Subscribe to MarketBeat All Access for the recommendation accuracy rating
R. Kumar
Subscribe to MarketBeat All Access for the recommendation accuracy rating
UpgradeStrong-Buy
12/18/2024Truist Financial
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Lower TargetBuy ➝ Buy$36.00 ➝ $32.00+21.72%
12/10/2024Bank of America
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Reiterated RatingNeutral$29.00+11.03%
11/15/2024Wolfe Research
Subscribe to MarketBeat All Access for the recommendation accuracy rating
A. Hammond
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Initiated CoverageUnderperform$25.00-3.92%
10/30/2024Evercore ISI
Subscribe to MarketBeat All Access for the recommendation accuracy rating
U. Raffat
Subscribe to MarketBeat All Access for the recommendation accuracy rating
UpgradeStrong-Buy
10/23/2024Cantor Fitzgerald
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Reiterated RatingOverweight ➝ Overweight$45.00 ➝ $45.00+55.93%
10/17/2024Sanford C. Bernstein
Subscribe to MarketBeat All Access for the recommendation accuracy rating
C. Breen
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Initiated CoverageMarket Perform$32.00+7.89%
8/7/2024Daiwa America
Subscribe to MarketBeat All Access for the recommendation accuracy rating
N. Nakagiri
Subscribe to MarketBeat All Access for the recommendation accuracy rating
UpgradeModerate Buy ➝ Strong-Buy
8/7/2024Daiwa Capital Markets
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 UpgradeNeutral ➝ Outperform$28.00 ➝ $34.00+14.21%
7/31/2024Barclays
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Boost TargetEqual Weight ➝ Equal Weight$30.00 ➝ $32.00+4.51%
7/31/2024Wells Fargo & Company
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Boost TargetEqual Weight ➝ Equal Weight$28.00 ➝ $30.00-3.23%
5/2/2024Morgan Stanley
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Boost TargetEqual Weight ➝ Equal Weight$28.00 ➝ $29.00+4.28%
5/2/2024BMO Capital Markets
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Reiterated RatingOutperform ➝ Outperform$33.00 ➝ $36.00+30.62%
3/22/2024Argus
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 DowngradeBuy ➝ Hold
1/4/2024TD Cowen
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 DowngradeOutperform ➝ Market Perform$32.00+7.67%
10/16/2023JPMorgan Chase & Co.
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Lower TargetNeutral ➝ Neutral$36.00 ➝ $34.00+0.71%
10/16/2023Jefferies Financial Group
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 UpgradeHold ➝ Buy$38.00 ➝ $39.00+21.46%
7/14/2023HSBC
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Initiated CoverageBuy$50.00+38.66%
6/29/2023Credit Suisse Group
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 DowngradeOutperform ➝ Neutral$47.00 ➝ $40.00+10.22%

Analyst ratings data on MarketBeat is provided by Benzinga and other data providers. This page was last refreshed on Wednesday at 07:34 PM ET.


Should I Buy Pfizer Stock? PFE Pros and Cons Explained

These pros and cons were generated based on recent news and financial data from MarketBeat in order to provide readers with the fastest and most accurate insights. They were last updated on Saturday, April 5, 2025. Please send any questions or comments about these Pfizer pros and cons to contact@marketbeat.com.

Pfizer
Bull Case

green Wall Street bull icon

Here are some ways that investors could benefit from investing in Pfizer Inc.:

  • Pfizer Inc. reported a significant earnings per share (EPS) of $0.63 for the latest quarter, surpassing the consensus estimate of $0.48, indicating strong financial performance and effective management.
  • The company experienced a revenue increase of 24.7% compared to the same quarter last year, with total revenue reaching $17.76 billion, showcasing robust growth potential.
  • Pfizer Inc. has a favorable average target price of $31.92, suggesting potential upside for investors based on analyst ratings, which include several "buy" and "strong buy" recommendations.
  • Recent insider buying activity, including a notable purchase by Director Ronald E. Blaylock, indicates confidence in the company's future performance, as insiders often have valuable insights into the company's prospects.
  • The current stock price is $22.99, which is near its 52-week low of $22.95, potentially presenting a buying opportunity for investors looking for value in a well-established biopharmaceutical company.

Pfizer
Bear Case

red Wall Street bear icon

Investors should be bearish about investing in Pfizer Inc. for these reasons:

  • Despite recent growth, Pfizer Inc.'s stock has seen a decline of 5.4%, which may raise concerns about its short-term performance and market volatility.
  • The company has a relatively low net margin of 12.62%, which could indicate challenges in maintaining profitability compared to competitors in the biopharmaceutical sector.
  • With a debt-to-equity ratio of 0.63, while manageable, it suggests that the company is somewhat reliant on debt financing, which could pose risks if market conditions change.
  • Analysts have issued a mix of ratings, with one sell rating and several hold ratings, indicating uncertainty about the stock's future performance and potential for growth.
  • Institutional investors hold a significant 68.36% of the company's stock, which may lead to increased volatility if large shareholders decide to sell their positions.

PFE Forecast - Frequently Asked Questions

According to the research reports of 17 Wall Street equities research analysts, the average twelve-month stock price forecast for Pfizer is $31.07, with a high forecast of $45.00 and a low forecast of $24.00.

17 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Pfizer in the last twelve months. There is currently 1 sell rating, 8 hold ratings, 5 buy ratings and 3 strong buy ratings for the stock. The consensus among Wall Street analysts is that investors should "moderate buy" PFE shares.

According to analysts, Pfizer's stock has a predicted upside of 38.10% based on their 12-month stock forecasts.

Over the previous 90 days, Pfizer's stock had 1 upgrade by analysts.

Pfizer has been rated by research analysts at Citigroup, Guggenheim, Hsbc Global Res, The Goldman Sachs Group, and UBS Group in the past 90 days.

Analysts like Pfizer less than other "medical" companies. The consensus rating score for Pfizer is 2.59 while the average consensus rating score for "medical" companies is 2.82. Learn more on how PFE compares to other companies.


This page (NYSE:PFE) was last updated on 4/9/2025 by MarketBeat.com Staff
From Our Partners